May 28,2024

Lilly to Participate in Goldman Sachs 45th Annual Global Healthcare Conference

 Eli Lilly and Company will participate in the Goldman Sachs 45th Annual Global Healthcare Conference on June 10, 2024. Patrik Jonsson, executive vice president, president of Lilly Diabetes and Obesity, and president of Lilly USA, will participate in a fireside chat at 4 p.m. Eastern time.

CONFERENCES
View Analyst & Ambassador Comments
Go to original news
Nov 29,2022

Dexcom, Abbott ask for another trial in CGM patent spat

Abbott and Dexcom are seeking a new trial in their ongoing patent dispute over continuous glucose monitors (CGMs). In March, a Delaware court found Dexcom violated one of Abbott's patents related to its FreeStyle Libre sensors but did not infringe on two others, with one patent deemed invalid. Despite the court's decision for a future trial to assess damages, both companies now seek broader judgments. Abbott claims Dexcom's failure to redesign its G6 CGM constitutes willful infringement, while Dexcom argues that Abbott's closing arguments prejudiced the jury. Both sides prefer Judge Kent A. Jordan to rule in their favor. The case includes other ongoing litigation in Europe.

#cgm

View Analyst & Ambassador Comments
Go to original news
May 29,2024

Dexcom Announces Upcoming Conference Presentation

Dexcom announced that Jereme Sylvain, Executive Vice President and Chief Financial Officer, will present an update on the company at the William Blair 44th Annual Growth Stock Conference on Wednesday, June 5th. The live presentation is scheduled to begin at approximately 4:20 PM EST and will be concurrently webcast.

CONFERENCES
View Analyst & Ambassador Comments
Go to original news
May 24,2024 TOP STORY

Biosensor technology company Allez Health secures $60M

Allez Health, a California-based company formerly known as Zense-Life, has secured $60 million in Series A+ financing, led by Osang Healthcare with participation from existing investors. Allez Health specializes in continuous glucose monitoring (CGM) biosensor technology aimed at enhancing patient performance through comprehensive health data analysis. The company’s leadership team includes former Dexcom executives, with CEO Leif Bowman, CTO Robert Boock, and Chief Science Officer Ted Zhang all having significant experience from Dexcom. The funding will support operations, regulatory filings, manufacturing scaling, and clinical trials.

FUNDING SERIES A

#cgm

View Analyst & Ambassador Comments
Go to original news
May 23,2024

Tandem Diabetes Care Announces Upcoming Conference Presentation

Tandem Diabetes Carey announced that management will present a company update at the Jefferies Global Healthcare Conference on Thursday, June 6, 2024 at 8:00am Eastern Time (5:00am Pacific Time).

View Analyst & Ambassador Comments
Go to original news
May 24,2024 TOP STORY

FDA approves hybrid closed-loop insulin delivery app from CamDiab

CamDiab announced that its CamAPS FX app, an advanced adaptive closed-loop artificial pancreas for type 1 diabetes management, received FDA authorization as an interoperable automated glycemic controller device (iAGC). The Android app, which integrates with compatible insulin pumps and continuous glucose monitors (CGMs) like the Dexcom G6 and FreeStyle Libre 3, is approved for users aged two and older, including pregnant women. Already holding CE mark approval in Europe and the UK, CamAPS FX is available in multiple countries and continues to expand.

REGULATORY FDA

#closed loop

#mobile app

View Analyst & Ambassador Comments
Go to original news
May 15,2024 TOP STORY

DARIOHEALTH REPORTS FIRST QUARTER 2024 FINANCIAL AND OPERATING RESULTS

DarioHealth reported its financial results for the Q1 2024, revealing a revenue of $5.8 million, which represents an 18.5% decrease from $7.1 million in the same quarter of the previous year but a notable 59% increase from $3.6 million in the Q4 2023. This year-over-year decrease was primarily due to a decline in revenues from strategic partner channels, partially offset by the addition of revenues from the recent acquisition of Twill. The company's B2B2C revenue showed impressive growth, reaching $3.47 million, up 176% from $1.26 million in the first quarter of 2023 and 210% from $1.12 million in the previous quarter. Operating expenses rose to $20.3 million from $15.6 million in the first quarter of 2023 and $14.3 million in the previous quarter, mainly due to costs associated with the Twill acquisition and increased stock-based compensation.

View Analyst & Ambassador Comments
Go to original news
May 22,2024

Ypsomed significantly increases its operating profit and plans to have two independent business areas

Ypsomed has significantly increased its operating profit and plans to establish two independent business areas. The company, which focuses on self-treatment solutions and injection systems for biopharmaceutical drugs and biosimilars, reported consolidated sales of CHF 548.5 million for the financial year 2023/24, with a substantial rise in operating profit to CHF 86.2 million. For diabetes care, Ypsomed's mylife YpsoPump system saw a 69% increase in commercial sales. The company aims to strengthen its diabetes care division by creating a new, independent Diabetes Care company under Ypsomed Holding AG. Ypsomed is also making strides in securing regulatory approvals for its products, including applications submitted to the FDA and Health Canada for the mylife YpsoPump system. The company expects to achieve break-even in the Diabetes Care segment by the fourth quarter of the current financial year.

View Analyst & Ambassador Comments
Go to original news
May 20,2024

The King’s Fund Digital health and care conference: innovation, problem-solving and understanding controversy

The King’s Fund Digital Health and Care Conference on July 17th, 2024, will focus on the future trajectory of healthcare delivery through innovative technologies. This event, featuring panel discussions, presentations, and workshops, will explore strategies for digital transformation aimed at delivering person-centered care, enhancing service integration, monitoring patients, and improving healthcare access in underserved or remote areas. Key sessions will delve into the impact of technologies like genomic testing, robotics, artificial intelligence, and smart supply chains on care providers and recipients.

CONFERENCES
View Analyst & Ambassador Comments
Go to original news
May 22,2024

Sustained Effectiveness of an Advanced Hybrid Closed-Loop System in a Cohort of Children and Adolescents With Type 1 Diabetes: A 1-Year Real-World Study

The study aimed to assess glucose metrics and identify predictors of glycemic outcomes in children and adolescents during their first year using the MiniMed 780G system. The longitudinal, real-world study involved 368 children and adolescents with type 1 diabetes (T1D) who began using SmartGuard technology from June 2020 to June 2022. Data were collected at baseline (15-day run-in period), 2 weeks after activating automatic mode, and every 3 months thereafter. The impact of various factors on glycemic outcomes after one year of using MiniMed 780G was evaluated. After one year, time in range (TIR) was significantly higher than at baseline (75.3% vs. 62.8%). The mean glycated hemoglobin (HbA1c) was lower (6.9% vs. 7.4% in the previous year). Higher TIR was linked to fewer automatic correction boluses, fewer SmartGuard exits, and longer time in automatic mode. The study demonstrates the sustained effectiveness of MiniMed 780G in improving glycemic outcomes for youth with T1D. The findings suggest that even those with low initial therapeutic engagement can benefit from SmartGuard technology.

CLINICAL STUDY

#closed loop

View Analyst & Ambassador Comments
Go to original news
Subscribe to DIABETES